Latest Lung Cancer Updates from ESMO 2014 – Advances in ALK Positive NSCLC by Dr. Sunil Verma
Author: Editor
Dr. James Brugarolas, M.D., Ph.D. Kidney Cancer Program Leader Associate Professor of Internal Medicine & Developmental Biology University of Texas Southwestern Medical Center discusses RCC Classification at the Kidney Cancer meeting in Chicago
Bernard J. Escudier, M.D. accepts the 2014 Eugene P. Schonfeld Award at the Kidney Cancer meeting in Chicago
Dr. Hiral D. Parekh, M.D. discusses Cost Analysis of an Initial Observation Approach in Metastatic Renal Cell Carcinoma at the Kidney Cancer meeting in Chicago
Dr. Laurence Albiges, M.D., Ph.D. discusses Differential expression of c-MET between primary and metastatic sites in clear cell Renal Cell Carcinomas (ccRCCs) at the Kidney Cancer meeting in Chicago.
Dr. Andre P. Fay, M.D. discusses Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-targeted Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mRCC) at the Kidney Cancer meeting in Chicago
Dr. Joshua Lang, M.D., M.S. discusses Development of Pharmacodynamic Biomarkers in Circulating Renal Cancer Cells at the Kidney Cancer meeting in Chicago
Dr. Andrew G. Winer discusses Tumor Purity and Immune Cell Infiltration as a Prognostic Risk Predictor for Clear Cell Renal Cell Carcinoma (ccRCC)
Dr. David Kwiatkowski talks about The mTOR signaling pathwayWho responds to rapalogs and why? at the Kidney Cancer meeting in Chicago.
Dr. Harriet Kluger, M.D.Associate Professor Yale Cancer Center discusses The Met Pathway as a Target in RCC at the Kidney Cancer meeting in Chicago
Dr. David F. McDermott discusses Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) at the Kidney Cancer meeting in Chicago
Dr. Thai Ho, M.D., Ph.D.Mayo Clinic Arizona discusses The Evolving Role of Chromatin and Epigenetics in RCC at the Kidney Cancer meeting in Chicago
Dr. Toni K. Choueiri discusses Risk Factors and a Model to Predict Toxicity-related Treatment Discontinuation in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy: Results from the International Metastatic RCC Database Consortium (IMDC)
Dr. Sumanta K. Pal, MD;1 Min Li, PhD;2 Xiwei Wu, PhD;3 Paul Frankel, PhD2 Â 1Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA; 2Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA; 3Department of Molecular & Cell Biology, City of Hope Comprehensive Cancer Center, Duarte, CA discusses Bacteriomic profiling reveals potential etiology for vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI)-related diarrhea in patients with metastatic renal cell carcinoma (mRCC) at the Kidney Cancer meeting in Chicago
Dr. Georg A. BjarnasonDivision of Medical OncologySunnybrook Odette Cancer CentreAssociate Professor, Faculty of Medicine, University of Toronto discusses Dose Reduction or Treatment Interruption Pro: Treatment Interruption and individualized dose/schedule alterationIndividualized Sunitinib as an example? at the Kidney Cancer meeting in Chicago
Dr. David I. Quinn MBBS (Hons) PhD FRACP FACP Associate Professor of Medicine Chief, Section of GU Medical Oncology Division of Medical Oncology Medical Director, Norris Cancer Hospital & Clinics Co-Leader, Developmental Therapeutics Program Member, USC Institute of Urology Kenneth J. Norris Comprehensive Cancer Center Keck School of Medicine University of Southern California discusses Dose Reduction or TreatmentInterruption: Pro Dose Reduction at the Kidney Cancer meeting in Chicago
Dr. Frede Donskov, M.D., PhD Chair, Danish Renal Cancer Group, DARENCA Aarhus University Hospital Denmark discusses Toxicity as a Biomarker at the Kidney Cancer meeting in Chiacgo
Suzanne L. Topalian of Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center discusses Biomarkers for PD-1 checkpoint inhibition at the Kidney Cancer meeting in Chicago
Dr. Drew Pardoll of Johns Hopkins discusses Basic Concepts and Future Horizons in Cancer Immunotherapy at the Kidney Cancer Meeting in Chiacgo
Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Department of Hematology/Oncology discusses Combination immunotherapy + VEGF targeted therapy is the optimal systemic strategy for metastatic RCC at the Kidney Cancer Meeting in Chiacgo
M. Dror Michaelson, MD PhD MGH Cancer CenterBoston, MA discusses how TKIs are the Optimal Front-Line mRCC Treatment
Dr. Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center discusses the Optimal Front-Line Treatment for mRCC
Toni K. Choueiri, MD Clinical Director and Kidney Cancer Center Director The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute Brigham and Womens Hospital presents Clinical Trials in non-clear cell RCC: ESPN, ASPEN and beyond at the Kidney Cancer Association meeting in Chicago 2014
Ari Hakimi MD Assistant Professor Urologic Oncology Affiliate Department of Computational Biology MSKCC presents Genomic Characterization of Sarcomatoid Clear Cell RCC at the Kidney Cancer Association meeting in Chicago 2014
Jianjun Gao, MD, PhD Department of Genitourinary Oncology MD Anderson Cancer Center presents Molecular Characterization of Renal Medullary Carcinoma at the Kidney Cancer Association meeting in Chicago 2014
Gabriel G. Malouf, MD, PhD Assistant professor Department of medical oncology Pitié-Salpêtrière Hospital, Paris, France discusses Translocation Renal Cell Carcinomas: Molecular insights and Future Directions at the Kidney Cancer Association meeting in Chiacgo 2014
Laurence Albiges, MD, PhD Lank Center for Genitourinary Oncology presents Papillary Renal Cell Carcinoma at the Kidney Cancer Association meeting in Chicago 2014
James Hsieh MD PhD MSKCC Translational Kidney Cancer Research Program (TKCRP) presents13thIKCS Chicago Rare Kidney Cancer:Chromophobe RCC at the Kidney Cancer Association meeting in Chicago 2014
Michael L. Blute Sr. MD Chief Urology MGH Walter S. Kerr Jr. Professor of Surgery Harvard Medical School presents Case Presentations Kidney Cancer Association meeting in Chicago 2014
Michael L. Blute Jr of MD Anderson presents the Recurrence After Surgery in Non-metastatic RCC with Thrombus; Risk Factors From A Contemporary Multicenter Analysis at the Kidney Cancer Association meeting in Chicago 2014
Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology discusses Cytoreductive Nephrectomy at the Kidney Cancer Association meeting in Chicago 2014
Sarah P. Psutka MD Fellow in Urologic Oncology Mayo Clinic, Rochester, MN presents the Latest On IVC Tumor Thrombus at the Kidney Cancer Association meeting in Chicago 2014
Jonathan Coleman, MD Memorial Sloan-Kettering Cancer Center Weill – Cornell University Medical College presents Kidney Cancer Management:The Role of Lymph Node Dissection at the Kidney Cancer Association meeting in Chicago 2014
At the iwNHL 2014, Prof Francesco D’Amore (Aarhus University, Aarhus, Denmark) interviews Dr Elaine Jaffe (National Cancer Institute, Maryland, USA) and Prof Laurence de Leval (IUP Institut universitaire de pathologie, Lausanne, Switzerland) about their involvement at this workshop. Dr Jaffe describes the important abnormal contribution of B-cell proliferation in angioimmunoblastic T-cell lymphoma and other T-cell lymphomas of follicular T-helper cell derivation. As a result, a neoplastic precursor cell is speculated. Prof de Leval describes recent sequencing discoveries in peripheral T-cell lymphomas that have provided new insight in tumour understanding.
Thomas D. Atwell, MD presents Ablation of larger and recurrent tumors at the Kidney Cancer Association meeting in Chicago 2014
R. Houston Thompson, MD of the Mayo Clinic presents NCCN and AUA GUIDELINES FOR RCC: DO THEY EFFECTIVELY CAPTURE RECURRENCES FOLLOWING NEPHRECTOMY? at the Kidney Cancer Association meeting in Chicago 2014
Joel Prince of The University of Wisconsin School of Medicine and Public Health presents Patient and Tumor Characteristics Predict Indeterminate Renal Mass Biopsy Findings
Jose A. Karam, MD Assistant Professor Department of Urology MD Anderson presents Locally Advanced RCC: Neoadjuvant Targeted Therapy
Tony Finelli MD, MSc, FRCSC GU Site Lead, Princess Margaret Cancer Center GU Lead, Cancer Care Ontario Associate Professor, University of Toronto presents Quality Indicators in Kidney Cancer Care at the Kidney Cancer Assoication meeting in Chicago 2014
Lara Barbara – Breast Cancer Survivor NSHOA Treats Patients with Chemo and Hugs brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)
Michael Murray – Primary Goal for Everyone at NSHOA is Patient Care brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN) Â Â Â Â medical oncology, nshoa, the community oncology alliance (coa), coa, the coa patient advocacy network (cpan), cpan
Dr. Ron Burkes commenting on the results of the Lux-Lung8 Trial from ESMO 2014
Dr. Natasha Leighl, lead study author, on the newsiest results on the activity of pembrolizumab in lung cancer
Dr. Edith Perez speaking on the expanded results of the ALTTO breast cancer trial
Dr. Sunil Verma providing a comprehensive update on the latest lung cancer updates from ESMO 2014
Don Marx – Care for Today, Research for Tomorrow brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)
Dr. Tewari at ESMO 2014 on latest advanced cervical cancer therapies
Dr. Teresa Petrella and Dr. Catalin Mihalcioiu speaking on combination therapies in melanoma.
Mark Levine – CFO North Shore Hematology Oncology Focused on Patient Care brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)
Immuno-Oncology: Shaping the Present, Transforming the Future and Raising the Bar in Oncology – from Best of ASCO Canada 2014